Bowel/fecal incontinence refers to a patient’s inability to control bowel movements, which results in involuntary loss of solid or liquid stool. It is caused due to diarrhea, constipation, weaker muscle tone (that controls the opening of the anus), and chronic medical conditions (such as diabetes, multiple sclerosis, and nerve damage). The clinical devices used to manage bowel activity are called bowel management systems.

The global bowel management systems market is projected to reach USD 2.07 billion by 2023, at a CAGR of 3.5%. Some of the major factors driving the growth of this market are: expanding target patient population, rapidly growing geriatric population, availability of technologically advanced bowel management products, and favorable reimbursement scenario in developed countries.

Market Dynamics

Driver: Favorable reimbursement scenario in developed countries

The developed countries are reported to have favorable reimbursement scenarios for bowel management products, owing to which the demand for these products is expected to grow positively during the study period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=45043428

Restraint: Patient preference for non-invasive clinical management of FI

Currently, FI can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter, and the creation of a stoma. These often require long-term patient rehabilitation and maybe highly inconvenient and even severely painful.

Adult patients segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period

The bowel management systems market is segmented, by patient type, into adult and pediatric patients. The adult patients segment is expected to register the highest growth rate in the bowel management systems market during the forecast period, owing to the factors such as the significant prevalence of FI among adults, increased public-private initiatives to enhance patient awareness related to effective FI management, and availability of advanced bowel management products.

The home care segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period

The bowel management systems market is segmented, by end user, into home care and hospitals & ambulatory surgery centers. The home care segment is expected to register the highest growth rate of the bowel management systems market during the forecast period, owing to the factors such as the significant usage and growing adoption of bowel management products in home care settings, and need for device replacement on a regular basis.

In 2018, Europe accounted for the largest share of the bowel management systems market

Geographically, the bowel management systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe accounted for the largest share of the market in 2018. The large share can be attributed to the significant disease (colorectal/bladder cancer & IBD) burden, favorable reimbursement scenario, and the increase in its geriatric population.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=45043428

Global Leaders:

An analysis of market developments between 2015 and 2018 revealed that growth strategies such as product launches and approvals, agreements, expansions, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the bowel management systems market. Among these, product launches and approvals were the most widely adopted growth strategies

Some of the major players operating in the bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (US), B. Braun (Germany), C.R. Bard (US), Consure Medical (India), Cogentix Medical (US), Aquaflush Medical Limited (UK), Axonics Modulation Technologies (US), ConvaTec (UK), Hollister (US), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (US), Welland Medical limited (UK), and Wellspect HealthCare (Sweden).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]